Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NDI-101150 |
Synonyms | |
Therapy Description |
NDI-101150 inhibits MAP4K1 (HPK1), which may prevent immunosuppression in the tumor microenvironment, potentially inducing a cytotoxic T-lymphocyte (CTL) response against tumor cells and resulting in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3083); NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NDI-101150 | NDI 101150|NDI101150 | MAP4K1 Inhibitor 8 | NDI-101150 inhibits MAP4K1 (HPK1), which may prevent immunosuppression in the tumor microenvironment, potentially inducing a cytotoxic T-lymphocyte (CTL) response against tumor cells and resulting in antitumor activity (J Clin Oncol 42, 2024 (suppl 16; abstr 3083); NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05128487 | Phase Ib/II | NDI-101150 NDI-101150 + Pembrolizumab | A Study of NDI 1150-101 in Patients With Solid Tumors | Active, not recruiting | USA | 0 |